The quality of evidence is downgraded by study limitations (lack of blinding, unclear allocation concealment).
A Cochrane review «Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection»1 «Henriquez-Camacho C, Gotuzzo E, Echevarria J et al. Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection. Cochrane Database Syst Rev 2016;(1):CD007745. »1 included 7 studies with a total of 1147 subjects.
In trials comparing ivermectin with albendazole, parasitological cure was higher with ivermectin (RR 1.79, 95% CI 1.55 to 2.08; 478 participants, four trials). There were no statistically significant differences in adverse events (RR 0.80, 95% CI 0.59 to 1.09; 518 participants, four trials).
In trials comparing ivermectin with thiabendazole, there was little or no difference in parasitological cure (RR 1.07, 95% CI 0.96 to 1.20; 467 participants, three trials). However, adverse events were less common with ivermectin (RR 0.31, 95% CI 0.20 to 0.50; 507 participants; three trials).
In trials comparing different dosages of ivermectin, taking a second dose of 200 μg/kg of ivermectin was not associated with higher cure in a small subgroup of participants (RR 1.02, 95% CI 0.94 to 1.11; 94 participants, two trials).
Dizziness, nausea, and disorientation were commonly reported in all drug groups. There were no reports of serious adverse events or death
Date of latest search: 24-8-2015